#Neuronyx donna lethal serial#

Prior to her current role, Rana was a Transaction alist in Worldwide Business Development at Pfizer where she was responsible for negotiating and transacting licenses, acquisitions, and partnerships across therapeutic areas. ( Stevenage, UK), Blade Therapeutics (South San Francisco, CA), RefleXion Medical (Hayward, CA), Montis (Leuven, Belgium), Biograph55 (San Francisco, CA), Jnana Therapeutics (Boston, MA), Arkuda (Cambridge, MA), and the Dementia Discovery Fund (London, UK) among others. (San Francisco, CA), Autifony Therapeutics Ltd. She currently has responsibility for Pfizer’s investments in ReCode Therapeutics (Menlo Park, CA Dallas, TX), Vivet Therapeutics (Paris, France), Mitokinin, Inc. Rana leverages her preclinical, clinical, and business development experience to assess, invest in, and manage equity investments for Pfizer Ventures. Rana Al-Hallaq, PhD is Executive Director and Partner at Pfizer Ventures. She obtained her venia legendi at the Charite, Berlin University in 2004 she is a reviewer for the German Ministry of Research and member of two supervisory boards in Germany: 4SC AG since 2012, and Paion AG since 2017. She trained in psychiatry and neurology at the Max Planck Institute of Psychiatry (in Munich), and is board certified in Germany.

Irina has an MD from the Technical University, Munich (Germany), and a PhD in neurophysiology from the University of Edinburgh, UK. Before joining Triplet Therapeutics, Inc., she was VP of Translational Medicine and Development at Wave Life Sciences in Cambridge, MA, developing stereopure nucleic acid therapeutics for rare genetic diseases. She has gained experience with development of small molecules, biologics as well as nucleic acid therapeutics, in a number of global pharma and biotech organizations in the US and Europe. Irina has worked in drug development for over 18 years, with a focus on translational medicine and early development in neuroscience, but also ophthalmology and immunology. He is an avid mountain biker, snowboarder and trail runner. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He served as Intellia’s President and CEO from inception until December 2017. Currently he is also a venture partner at Atlas Venture and is Chairman of the Board of Directors of F-star and Akrevia Therapeutics. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe.

He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets.

#Neuronyx donna lethal serial#

He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. Nessan Bermingham is Executive Chairman of Triplet Therapeutics, Inc.